The pharmacology of hormone therapy in menopause, selective estrogen receptor modulators (SERMs), and gonadotropin-releasing hormone (GnRH) modulators encompasses some of the most clinically consequential and most frequently examined areas in gynecological pharmacology. Rational prescribing in these areas requires understanding of the Women's Health Initiative (WHI) trial findings and the subsequent recalibration of risk-benefit in younger symptomatic menopausal women, the route-dependent risk differences between oral and transdermal estrogen, the tissue-selective ER pharmacology underlying SERM clinical profiles, and the mechanistic distinction between GnRH agonist-mediated receptor downregulation and the immediate competitive antagonism produced by GnRH antagonists. This module covers these areas with the depth required to address the nuanced clinical questions that arise in T3 vignettes and T4 extended cases involving menopausal women with comorbidities, breast cancer survivors, women with endometriosis or fibroids requiring pharmacological management, and patients in whom sequential or combination hormonal manipulation is planned.
The Women's Health Initiative (WHI) comprised two parallel randomized controlled trials of postmenopausal hormone therapy (HT): one arm randomized women with an intact uterus to conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day versus placebo, and a second arm randomized hysterectomized women to CEE 0.625 mg/day alone versus placebo. The CEE+MPA arm was stopped prematurely in 2002 after a mean of 5.2 years when the predefined stopping rule for invasive breast cancer was crossed. The CEE-alone arm continued until 2004 and was stopped for an increased stroke risk. These two trials have distinctly different risk profiles and must not be conflated in clinical reasoning or examination questions: the CEE-alone arm showed no increase in breast cancer risk and a statistically non-significant reduction, while the CEE+MPA arm showed a hazard ratio for breast cancer of 1.26 (95% CI 1.00 to 1.59), an increase that became significant after longer follow-up in the intervention group.1
The absolute risk increments reported in the WHI CEE+MPA arm, expressed as excess events per 10,000 woman-years compared to placebo, included approximately 8 additional cases of invasive breast cancer, 7 additional coronary heart disease (CHD) events, 8 additional strokes, and 18 additional venous thromboembolic events (VTE). In the same analysis, hormone therapy reduced the incidence of colorectal cancer by approximately 6 cases per 10,000 woman-years, reduced hip fractures by approximately 5 per 10,000 woman-years, and reduced total fractures substantially. The net harm-benefit calculus differed substantially by age and time since menopause, a finding that was not emphasized in the original 2002 publication but has become central to the subsequent reanalysis and to current clinical guidelines.12
The timing hypothesis, formalized through post-hoc analyses of the WHI and supported by the Kronos Early Estrogen Prevention Study (KEEPS) and the Early versus Late Intervention Trial with Estradiol (ELITE),3 holds that the cardiovascular risk-benefit of HT is entirely dependent on when therapy is initiated relative to menopause onset. Women who initiate HT within 10 years of menopause or before age 60 show a favorable or neutral cardiovascular profile, whereas women who initiate HT more than 10 years after menopause or after age 60 show net cardiovascular harm, particularly in relation to coronary events and stroke. The biological basis of this timing effect is thought to involve the state of coronary atherosclerosis at the time of estrogen exposure: in early menopause with largely healthy endothelium and minimal plaque, estrogen exerts anti-inflammatory, vasodilatory, and antiatherogenic effects via endothelial ERα activation; in late menopause with established subclinical atherosclerosis, estrogen may destabilize vulnerable plaques or promote thrombosis at plaque fissures through prothrombotic mechanisms.23
The original WHI population had a mean age of 63 years at enrollment, more than a decade past the mean menopause age of 51, meaning the trial was not designed to answer the clinical question most relevant to symptomatic perimenopausal women. Current guidance from the North American Menopause Society (NAMS) and the British Menopause Society (BMS) reflects this recalibration, stating that for healthy women under 60 or within 10 years of menopause who have bothersome vasomotor symptoms or other menopause-related quality-of-life impairment, the benefits of HT outweigh the risks in the absence of specific contraindications, and that HT should not be withheld on the basis of age alone if the woman is within this therapeutic window. The progestin type also matters: MPA used in the WHI arm carried a differential breast cancer signal compared to micronized progesterone, as demonstrated by the E3N (Etude Epidemiologique de femmes de la Mutuelle Generale de l'Education Nationale) French cohort study and supported by mechanistic data showing that MPA, unlike micronized progesterone, lacks the gamma-aminobutyric acid-A-receptor-mediated neuroactive metabolites that may have anti-proliferative breast effects.24
CEE + MPA (intact uterus): breast cancer HR 1.26, CHD increased, stroke increased, VTE increased. CEE alone (hysterectomized): no breast cancer increase, reduced hip fracture, increased stroke only. The progestin component drives the breast cancer signal. Applying the CEE+MPA risk data to transdermal estradiol plus micronized progesterone is not pharmacologically supported: different estrogen routes, different progestin types, different patient ages, and different baseline atherosclerosis burden all modify the risk profile substantially.
As established in Ova-01, oral estrogen undergoes hepatic first-pass metabolism that produces supraphysiological portal estrogen concentrations and stimulates hepatic synthesis of coagulation factors (factors VII, IX, X, fibrinogen), sex hormone-binding globulin (SHBG), angiotensinogen, and C-reactive protein (CRP). These hepatic effects are the mechanistic basis for the venous thromboembolism (VTE) risk elevation associated with oral hormone therapy (HT). Transdermal estradiol, delivered through the skin directly into the systemic circulation, bypasses the portal hepatic first-pass and does not produce the same degree of coagulation factor induction or angiotensinogen elevation, resulting in a substantially different risk profile. The ESTHER (Estrogen and Thromboembolism Risk) study, a multicenter French case-control study, demonstrated that oral estrogen use was associated with an approximately four-fold increased risk of VTE compared to non-users, while transdermal estrogen was not associated with an increased VTE risk at any dose studied. This finding has been replicated in multiple observational datasets and is reflected in a meta-analysis by Canonico et al. showing adjusted odds ratios for VTE of approximately 2.5 to 4.0 for oral estrogen versus 0.9 to 1.1 for transdermal estrogen compared to no HT.656
The clinical implication of the route-VTE relationship is most consequential in women with VTE risk factors including obesity, personal or family history of deep vein thrombosis (DVT) or pulmonary embolism (PE), known heterozygous thrombophilia (factor V Leiden heterozygosity, prothrombin G20210A heterozygosity), or immobility. In these women, transdermal estradiol is the preferred route if HT is clinically indicated, because observational data consistently support VTE-neutral status for transdermal estrogen even at therapeutic doses. Women with severe thrombophilia (homozygous factor V Leiden, protein C or S deficiency, antithrombin III deficiency) should generally be counseled that all forms of HT carry risk and that non-hormonal vasomotor symptom management should be offered first, although the absolute risk difference between oral and transdermal estrogen may still favor transdermal in these patients when quality-of-life impact of untreated symptoms is severe.5
The type of progestin used in HT also modifies the breast cancer risk signal. The E3N (Etude Epidemiologique aupres de femmes de la MGEN) prospective cohort study from France4 followed approximately 80,000 postmenopausal women and demonstrated that combined HT using estrogen plus medroxyprogesterone acetate (MPA) or norpregnane derivatives was associated with a two-fold increase in breast cancer risk, while combined HT using estrogen plus micronized progesterone or dydrogesterone was not associated with a statistically significant breast cancer risk increase. This differential is attributed to the distinct receptor profiles of MPA (synthetic progestin with glucocorticoid receptor [GR] and androgen receptor [AR] cross-reactivity) compared to micronized progesterone, whose gamma-aminobutyric acid-A-receptor-potentiating active metabolites (allopregnanolone and pregnanolone) may exert anti-proliferative effects in breast tissue that MPA does not share. The clinical recommendation emerging from these data is that when systemic progestin is required to protect the endometrium in a woman with an intact uterus, micronized progesterone (or dydrogesterone where available) should be preferred over MPA in women prioritizing breast cancer risk minimization.747
For women with an intact uterus, systemic progestin must be combined with systemic estrogen to prevent estrogen-induced endometrial hyperplasia and carcinoma: unopposed systemic estrogen in a woman with a uterus increases endometrial cancer risk four-fold after 3 years and ten-fold after 10 years of use. Progestin can be administered continuously (low-dose daily progestin with estrogen, producing amenorrhea) or sequentially (cyclic progestin for 10 to 14 days per month, producing a withdrawal bleed). Continuous combined regimens are generally preferred by postmenopausal women because they avoid scheduled bleeding, but they require a 3-month tolerance period during which irregular spotting may occur as the endometrium achieves atrophy. Sequential regimens are appropriate in perimenopausal women who still have some endogenous ovarian function and in whom the continuous combined regimen may produce erratic bleeding due to interaction with residual follicular activity. For hysterectomized women, progestin is not required, and estrogen alone (conjugated equine estrogens [CEE] or transdermal estradiol) is the appropriate and preferred regimen.2
In women requiring systemic HT for vasomotor symptoms who have a uterus, the combination of transdermal estradiol and oral micronized progesterone carries the most favorable safety data among available regimens: VTE-neutral (transdermal route), no breast cancer signal increase (micronized progesterone vs MPA), and preserved cardiovascular benefit profile in the timing-hypothesis-appropriate age group. This regimen was not used in the WHI, which tested oral CEE + MPA, making direct extrapolation of WHI risk data to this regimen pharmacologically unjustified.
Selective estrogen receptor modulators (SERMs) are a pharmacologically heterogeneous class of compounds that bind estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) and produce tissue-selective agonist or antagonist activity determined by the ligand-induced receptor conformation and the tissue-specific coactivator and corepressor profile. The tissue-selective activity of SERMs is the pharmacological basis for their clinical utility: a single agent can simultaneously antagonize ER in breast tissue (reducing proliferation and cancer recurrence risk), agonize ER in bone (maintaining bone mineral density [BMD]), and show variable agonist activity in the uterus and cardiovascular system. The molecular determinant of tissue selectivity is the specific three-dimensional conformation that each selective estrogen receptor modulator (SERM) induces in the ER ligand-binding domain (LBD), which determines which of the competing transcriptional coactivator and corepressor complexes engage at the activation function 2 (AF-2) surface and which downstream gene programs are activated or suppressed.8
Tamoxifen is a non-steroidal triphenylethylene derivative that acts as a competitive partial agonist at ERα. In breast tissue, tamoxifen induces a receptor conformation that recruits corepressors over coactivators, producing net antagonism and blocking the proliferative effects of estradiol on hormone receptor-positive breast cancer cells. In bone, tamoxifen acts as a partial agonist, maintaining BMD in postmenopausal women and reducing vertebral fracture risk. In the uterus, tamoxifen acts as a partial agonist, producing endometrial stimulation that increases the risk of endometrial hyperplasia and endometrial carcinoma approximately two-fold with long-term use; this is the primary serious adverse effect of tamoxifen in non-cancer populations. Tamoxifen is the standard adjuvant hormonal therapy for premenopausal women with hormone receptor-positive breast cancer, used for 5 to 10 years depending on recurrence risk, and remains appropriate in postmenopausal women when aromatase inhibitors are not tolerated.89
The critical pharmacokinetic feature of tamoxifen that is clinically actionable is its dependence on cytochrome P450 2D6 (CYP2D6)-mediated metabolism to its active metabolite endoxifen. Tamoxifen undergoes hepatic N-demethylation to N-desmethyltamoxifen (by CYP3A4) and then hydroxylation to endoxifen (by CYP2D6); endoxifen has approximately 30 to 100 times greater affinity for ER than tamoxifen itself and is responsible for the majority of tamoxifen's anticancer efficacy. CYP2D6 poor metabolizers (PMs), who have two non-functional CYP2D6 alleles, achieve endoxifen plasma concentrations approximately 75% lower than extensive metabolizers, and observational data support an association between poor metabolizer (PM) status and higher breast cancer recurrence rates in tamoxifen-treated patients. Potent CYP2D6 inhibitors, most prominently paroxetine and fluoxetine (selective serotonin reuptake inhibitors [SSRIs] commonly used for vasomotor symptoms in breast cancer survivors), reduce endoxifen levels by 60 to 75% in extensive metabolizers, functionally converting them to poor metabolizers. Venlafaxine (a serotonin-norepinephrine reuptake inhibitor [SNRI]) is a much weaker CYP2D6 inhibitor and is the preferred pharmacological treatment for vasomotor symptoms in women on tamoxifen.9
Raloxifene is a benzothiophene SERM that acts as an ERα antagonist in both breast and uterine tissue, unlike tamoxifen which shows partial ER agonism in the uterus. This tissue-selective profile makes raloxifene preferable to tamoxifen for breast cancer chemoprevention in postmenopausal women because it does not carry the endometrial cancer risk, though it is somewhat less effective than tamoxifen in reducing invasive breast cancer incidence, as demonstrated in the STAR (Study of Tamoxifen and Raloxifene) trial.10 The STAR trial enrolled approximately 19,000 postmenopausal women at increased breast cancer risk and found that tamoxifen and raloxifene produced equivalent reductions in invasive breast cancer incidence, but tamoxifen was superior in preventing non-invasive ductal carcinoma in situ (DCIS), while raloxifene produced fewer thromboembolic events and fewer cases of uterine cancer. Raloxifene also reduces vertebral fracture risk in postmenopausal women with osteoporosis and has been studied in cardiovascular risk reduction, though its net cardiovascular effect in high-risk women was neutral in the RUTH (Raloxifene Use for The Heart) trial.810
Ospemifene is an oral SERM approved for moderate to severe dyspareunia due to vulvovaginal atrophy (VVA) in postmenopausal women. It acts as an ERα agonist in vaginal epithelial tissue, increasing vaginal maturation index, reducing vaginal pH, and improving lubrication and dyspareunia, without requiring local vaginal application. Ospemifene has a neutral to mildly agonistic effect on the endometrium (producing a mild endometrial proliferative effect at higher doses) and acts as an ER antagonist in breast tissue. It carries a venous thromboembolism (VTE) risk similar to other SERMs and is contraindicated in women with active or prior VTE, undiagnosed uterine bleeding, or estrogen-sensitive malignancy. Hot flushes are the most common adverse effect, occurring in approximately 7% to 10% of users. In contrast to vaginal estrogen preparations, ospemifene is absorbed systemically and achieves therapeutic serum concentrations.8
Paroxetine is among the most potent CYP2D6 inhibitors used clinically. Co-prescription of paroxetine with tamoxifen in a breast cancer patient on adjuvant therapy effectively phenocopies CYP2D6 poor metabolizer status, reducing endoxifen exposure by up to 75% and potentially compromising the oncological benefit of tamoxifen. This interaction is not theoretical: population pharmacokinetic modeling predicts approximately 75 additional breast cancer deaths per 10,000 women treated for 5 years if paroxetine is used throughout tamoxifen therapy. The correct management is to switch to venlafaxine or gabapentin for hot flush management in women on tamoxifen. If an SSRI is needed, escitalopram and citalopram are weak CYP2D6 inhibitors and can be used with appropriate monitoring.
Gonadotropin-releasing hormone (GnRH) agonists are synthetic peptide analogues of endogenous GnRH that are resistant to enzymatic degradation and bind to GnRH receptors on pituitary gonadotrophs with high affinity and prolonged occupancy. The paradoxical therapeutic outcome of GnRH agonist administration is pituitary gonadotropin suppression rather than stimulation, and this result depends entirely on the pharmacokinetic distinction between pulsatile and continuous receptor stimulation. Endogenous GnRH is released in pulses every 60 to 120 minutes; this pulsatile pattern of receptor stimulation is required for sustained luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.11 Continuous receptor occupation by GnRH agonists desensitizes and downregulates the GnRH receptor population: the receptor undergoes internalization, the coupled G protein signaling cascade becomes uncoupled, and pituitary gonadotrophs cease responding to the continuous agonist signal. This receptor downregulation takes 2 to 4 weeks to develop and is accompanied by a fall in circulating LH and FSH to castrate or near-castrate levels, followed by a corresponding fall in ovarian estradiol to postmenopausal levels (below 30 to 50 picograms per milliliter).12
The initial flare phenomenon is an obligate pharmacodynamic consequence of beginning GnRH agonist therapy. For the first 1 to 2 weeks of treatment, before receptor downregulation occurs, the agonist produces paradoxical stimulation of LH and FSH release, causing a transient surge in estradiol (or testosterone in men) to supraphysiological levels. In the treatment of endometriosis, this initial flare can temporarily worsen pelvic pain and may produce flare-associated endometriotic lesion stimulation. In women with uterine fibroids, the initial estrogen flare may worsen fibroid-related symptoms transiently. In men with prostate cancer treated with GnRH agonists, the testosterone flare can precipitate symptomatic progression of metastatic disease (spinal cord compression, ureteral obstruction, pain flare) in those with high-burden disease, which is why antiandrogen co-administration for the first 4 weeks of GnRH agonist therapy is standard in men with high-volume metastatic disease. In women being treated for endometriosis or fibroids, the flare is generally tolerable but should be discussed as part of informed consent.12
Available GnRH agonist formulations include leuprolide acetate (intramuscular [IM] or subcutaneous depot formulations at 1-month, 3-month, or 6-month intervals; nasal spray form also available for endometriosis), goserelin acetate (subcutaneous depot implant at 1-month or 3-month intervals, implanted into the anterior abdominal wall), and nafarelin acetate (intranasal twice-daily spray for endometriosis). All produce equivalent degrees of gonadal suppression when used at appropriate doses, and the choice among agents is generally driven by patient preference, route of administration, and dosing convenience rather than pharmacological differences in efficacy or safety. After achieving steady-state receptor downregulation, all agents maintain estradiol suppression within the postmenopausal range, creating a state of reversible pharmacological hypogonadism whose principal side effects reflect estrogen deficiency: vasomotor symptoms (hot flushes), vaginal dryness, sleep disturbance, and bone mineral density (BMD) loss.12
Add-back therapy addresses the hypoestrogen consequences of GnRH agonist treatment, particularly BMD loss and vasomotor symptoms, by restoring a low level of estrogen while preserving the therapeutic benefit of gonadal suppression for the underlying condition. The pharmacological rationale rests on the differential estrogen threshold hypothesis: endometriotic lesions and uterine fibroids are more sensitive to estrogen stimulation than bone, the cardiovascular system, and brain, meaning that a low-dose estrogen replacement level that is insufficient to stimulate disease but sufficient to protect bone and quality of life can be achieved concurrently with GnRH agonist therapy. The standard add-back regimen is low-dose oral norethindrone acetate alone (5 mg/day) or combined estrogen-progestin (for example, conjugated equine estrogens [CEE] 0.625 mg plus norethindrone acetate 5 mg daily). Add-back therapy extends the safe duration of GnRH agonist use from approximately 6 months (beyond which BMD loss becomes clinically significant) to potentially 12 to 24 months or longer, supported by trial evidence showing preserved bone density with add-back compared to GnRH agonist monotherapy.12
Without add-back therapy, GnRH agonist-induced hypoestrogenism produces clinically significant BMD loss (1% to 3% per month at trabecular bone sites) that may not fully reverse after treatment cessation. Six months is the generally accepted maximum duration of GnRH agonist monotherapy for endometriosis or fibroids. Add-back therapy allows extension to 12 months or longer, with appropriate bone density monitoring. In adolescents, for whom peak bone mass acquisition is not yet complete, GnRH agonist use without add-back should be limited to 6 months or add-back should begin concurrently with treatment initiation.
GnRH antagonists are a newer class of GnRH receptor modulators that produce gonadal suppression through competitive receptor blockade rather than receptor downregulation. Unlike GnRH agonists, which require 2 to 4 weeks to achieve therapeutic suppression through the paradoxical desensitization mechanism, GnRH antagonists produce immediate and dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) within hours of the first dose by competitively occupying GnRH receptors and blocking endogenous GnRH signaling without any initial stimulatory phase. This mechanistic difference eliminates the flare phenomenon entirely and allows GnRH antagonists to be used without the need for antiandrogen pretreatment in men or flare-related symptom counseling in women. Cessation of GnRH antagonist therapy also results in rapid recovery of endogenous GnRH pulsatility and gonadotropin secretion, offering a more titratable and reversible suppression profile than depot GnRH agonists.13
Elagolix (Orilissa) is an oral, non-peptide, small-molecule GnRH receptor antagonist approved for the management of moderate to severe pain associated with endometriosis. Its key pharmacological advantage over depot GnRH agonists is dose-dependent, partially titratable suppression: at 150 mg once daily, elagolix produces partial suppression of estradiol, reducing mean estradiol levels to approximately 40 to 50 picograms per milliliter (low-normal premenopausal range), which provides significant pain reduction with less bone mineral density loss and fewer vasomotor symptoms compared to full suppression. At 200 mg twice daily, elagolix produces near-complete suppression of estradiol to postmenopausal levels (mean approximately 12 picograms per milliliter), producing greater pain reduction but also more vasomotor symptoms and bone mineral density (BMD) loss comparable to that seen with GnRH agonists. The Phase 3 ELARIS (ELAgolix Research in Endometriosis, Studies 1 and 2) trials demonstrated significant reductions in dysmenorrhea and non-menstrual pelvic pain scores compared to placebo at both doses over 6 months. Because of dose-dependent BMD loss, elagolix at 200 mg twice daily is approved for use up to 6 months, while the 150 mg once-daily dose is approved for up to 24 months.13
Relugolix (Orgovyx) is an oral GnRH antagonist with a rapid onset of action (testosterone suppression to castrate levels achieved in 95% of men within 4 weeks) approved for advanced prostate cancer; it was the first oral GnRH antagonist approved for this indication and demonstrated non-inferiority to leuprolide in the HERO (Relugolix for Prostate Cancer) trial with a significantly lower rate of major adverse cardiovascular events (MACE), possibly reflecting the absence of the testosterone flare and continuous rather than pulsatile LH and FSH suppression pattern. The combination tablet of relugolix 40 mg plus estradiol 1 mg plus norethindrone acetate 0.5 mg (Myfembree) is a fixed-dose combination approved for uterine fibroid-associated heavy menstrual bleeding in premenopausal women, exploiting the GnRH antagonist mechanism to suppress fibroid-stimulating estrogen and progesterone while the add-back components (estradiol and norethindrone acetate) protect against hypoestrogenic bone loss and vasomotor symptoms. The relugolix fibroid trials (LIBERTY Studies 1 and 2) demonstrated significant reductions in menstrual blood loss compared to placebo in women with uterine fibroids, with the combination tablet maintaining BMD over 24 weeks.14
Linzagolix (Yselty), a newer oral GnRH antagonist, has received approval in Europe for uterine fibroid-associated heavy menstrual bleeding, with or without add-back therapy, providing additional dosing flexibility. The common principle across GnRH antagonists in gynecological indications is that partial estrogen suppression with add-back avoids the adverse effects of full hypoestrogenism while maintaining therapeutic efficacy for estrogen-sensitive conditions, and that the no-flare property and rapid reversibility represent meaningful clinical advantages over depot GnRH agonist formulations, particularly when treatment duration or dose adjustment is likely to be individualized. Cytochrome P450 3A4 (CYP3A4) metabolizes elagolix, and co-administration with strong CYP3A4 inhibitors (such as ketoconazole or ritonavir-boosted antiviral regimens) increases elagolix exposure and is contraindicated or requires dose adjustment; strong CYP3A4 inducers reduce elagolix exposure and may compromise efficacy.13
GnRH agonists: continuous receptor stimulation → downregulation → suppression (delayed 2–4 weeks, flare period, depot formulations lasting 1–6 months, slow offset). GnRH antagonists: competitive blockade → immediate suppression (hours, no flare, oral daily dosing, rapid offset at cessation). Both achieve gonadal suppression, but antagonists are titratable, flare-free, and rapidly reversible. The clinical trade-off is that daily oral compliance is required for antagonists, whereas depot agonists provide compliance-independent sustained delivery.
Endometriosis is an estrogen-dependent inflammatory condition defined by the presence of endometrial glands and stroma outside the uterine cavity. Its pharmacological management targets the estrogen dependence of ectopic endometrial tissue through several overlapping mechanisms. First-line pharmacological treatment includes combined oral contraceptives (COCs), which suppress the cyclical estrogen and progesterone exposure that drives ectopic implant growth and bleeding, and progestin-only preparations (oral norethindrone acetate or medroxyprogesterone acetate [MPA], the levonorgestrel-intrauterine device [LNG-IUD], or the etonogestrel implant), which suppress endometrial proliferation through direct progestogenic action on the endometriotic stroma and by reducing circulating estrogen levels to a variable degree. The LNG-IUD has particular utility in endometriosis-associated dysmenorrhea because it delivers locally high LNG concentrations to the uterine and pelvic tissue environment, producing endometrial atrophy and reducing retrograde menstruation volume and frequency. While the LNG-IUD does not suppress pelvic peritoneal implants as effectively as systemic therapy, it is highly effective for the dysmenorrhea and heavy bleeding components of endometriosis and avoids systemic adverse effects.15
Second-line pharmacological treatment for endometriosis includes GnRH agonists with add-back therapy (as detailed in Section 4) and GnRH antagonists (as detailed in Section 5). Progestins at higher doses, including dienogest 2 mg/day (approved for endometriosis in many countries outside the USA) and oral norethindrone acetate at doses of 5 to 15 mg/day, also achieve effective suppression of endometriotic implants through direct progesterone receptor (PR)-mediated anti-proliferative and anti-inflammatory mechanisms, without the complete hypoestrogenism of GnRH-based therapies. The aromatase inhibitor (AI) letrozole has been used off-label for refractory endometriosis, exploiting the fact that endometriotic lesions overexpress aromatase (CYP19A1) locally and generate estrogen from androgen substrates, making local aromatase inhibition a plausible and sometimes effective therapeutic strategy when standard hormonal therapies have failed; AIs are typically combined with a progestin or combined oral contraceptive to prevent compensatory ovarian stimulation from the resulting low estrogen feedback.15
Uterine fibroids (leiomyomata uteri) are benign smooth muscle tumors whose growth is estrogen- and progesterone-dependent. Pharmacological management targets this hormonal dependency to reduce fibroid volume, heavy menstrual bleeding, and bulk symptoms. Progestins, contrary to what might be expected given that progesterone can promote fibroid mitogenic activity, are effective in reducing fibroid-related bleeding when delivered locally via the LNG-IUD, and the 52 mg LNG-IUD is a highly effective first-line pharmacological option for fibroid-related heavy menstrual bleeding when the fibroid anatomy permits IUD placement (fibroids that significantly distort the uterine cavity may preclude proper IUD positioning). Systemic MPA reduces fibroid volume less reliably than GnRH-based therapies, and its role in fibroid management is primarily for bleeding control rather than fibroid volume reduction.14
GnRH agonists reduce uterine and fibroid volume by 30% to 60% over 3 to 6 months through hypoestrogenic atrophy of fibroid tissue. This preoperative volume reduction is used to facilitate less invasive surgical approaches (laparoscopic myomectomy or hysterectomy where open surgery would otherwise be required), to reduce intraoperative blood loss, and to correct preoperative anemia. A critical pharmacological caveat is that the volume reduction achieved with GnRH agonist treatment reverses rapidly after cessation: fibroids typically regrow to pre-treatment size within 3 to 6 months of stopping therapy. GnRH agonists are therefore used as a bridge to surgery rather than as long-term standalone management for fibroids unless contraindication to surgery or patient preference precludes a surgical approach. The GnRH antagonist combination tablets (relugolix/estradiol/norethindrone acetate) represent the first approved long-term non-surgical pharmacological option for heavy uterine bleeding due to fibroids, with sustained efficacy demonstrated over 52 weeks in extension studies without the bone mineral density (BMD) concerns associated with prolonged GnRH agonist monotherapy.14
The 52 mg LNG-IUD effectively addresses the two shared symptoms of both endometriosis and uterine fibroids: dysmenorrhea and heavy menstrual bleeding. In endometriosis, high local LNG concentrations suppress ectopic endometrial proliferation and reduce retrograde menstruation. In fibroids (where the cavity is not significantly distorted), local endometrial atrophy from LNG profoundly reduces bleeding even when fibroids persist. The LNG-IUD thus provides long-term relief for the key symptoms of both conditions without systemic hypoestrogenism, making it the preferred initial pharmacological option in women who do not require reduction of pelvic implants or fibroid volume per se.
Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
doi:10.1001/jama.288.3.321Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
doi:10.1001/jama.2013.278040Hodis HN, Mack WJ, Henderson VW, et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231.
doi:10.1056/NEJMoa1505241Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–111.
doi:10.1007/s10549-007-9523-xCanonico M, Oger E, Plu-Bureau G, et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens. Circulation. 2007;115(7):840–845.
doi:10.1161/CIRCULATIONAHA.106.642280Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
doi:10.1136/bmj.k4810Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
doi:10.1016/S0140-6736(19)31709-XJordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205–213.
doi:10.1038/nrd1031Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 2008;83(1):160–166.
doi:10.1038/sj.clpt.6100367Vogel VG, Costantino JP, Wickerham DL, et al; National Surgical Adjuvant Breast and Bowel Project. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–2741.
doi:10.1001/jama.295.23.2727Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393–399.
doi:10.1016/0006-291x(71)90766-2Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol. 2002;99(5 Pt 1):709–719.
doi:10.1016/s0029-7844(02)01945-5Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.
doi:10.1056/NEJMoa1700089Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–642.
doi:10.1056/NEJMoa2008283Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
doi:10.1093/humrep/det457